{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T21:05:35Z","timestamp":1785618335266,"version":"3.56.0"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1248\/bpb.b20-00742","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:07:37Z","timestamp":1614550057000},"page":"461-464","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Bepridil and Pimozide, Existing Medicines Capable of Blocking T-Type Ca&lt;sup&gt;2+&lt;\/sup&gt; Channels, on Visceral Pain in Mice"],"prefix":"10.1248","volume":"44","author":[{"given":"Maho","family":"Tsubota","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Fukushi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsufumi","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Sekiguchi F, Kawabata A. T-type calcium channels: functional regulation and implication in pain signaling. <i>J. Pharmacol. Sci.<\/i>, <b>122<\/b>, 244\u2013250 (2013)."},{"key":"2","unstructured":"2) Weiss N, Zamponi GW. T-type calcium channels: from molecule to therapeutic opportunities. <i>Int. J. Biochem. Cell Biol.<\/i>, <b>108<\/b>, 34\u201339 (2019)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Snutch TP, Zamponi GW. Recent advances in the development of T-type calcium channel blockers for pain intervention. <i>Br. J. Pharmacol.<\/i>, <b>175<\/b>, 2375\u20132383 (2018).","DOI":"10.1111\/bph.13906"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Uchino T, Lee TS, Kaku T, Yamashita N, Noguchi T, Ono K. Voltage-dependent and frequency-independent inhibition of recombinant Ca<sub>v<\/sub>3.2 T-type Ca<sup>2+<\/sup> channel by bepridil. <i>Pharmacology<\/i>, <b>74<\/b>, 174\u2013181 (2005).","DOI":"10.1159\/000085329"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP. Differential inhibition of T-type calcium channels by neuroleptics. <i>J. Neurosci.<\/i>, <b>22<\/b>, 396\u2013403 (2002).","DOI":"10.1523\/JNEUROSCI.22-02-00396.2002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tsubota M, Matsui K, Nakano M, Kajitani R, Ishii Y, Tomochika K, Nishikawa Y, Fukushi S, Yamagata A, Sekiguchi F, Okada T, Toyooka N, Kawabata A. Essential role of Ca<sub>v<\/sub>3.2 T-type calcium channels in butyrate-induced colonic pain and nociceptor hypersensitivity in mice. <i>Eur. J. Pharmacol.<\/i>, <b>887<\/b>, 173576 (2020).","DOI":"10.1016\/j.ejphar.2020.173576"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hiramoto S, Tsubota M, Yamaguchi K, Okazaki K, Sakaegi A, Toriyama Y, Tanaka J, Sekiguchi F, Ishikura H, Wake H, Nishibori M, Nguyen HD, Okada T, Toyooka N, Kawabata A. Cystitis-related bladder pain involves atp-dependent HMGB1 release from macrophages and its downstream H<sub>2<\/sub>S\/Ca<sub>v<\/sub>3.2 signaling in mice. <i>Cells<\/i>, <b>9<\/b>, 1748 (2020).","DOI":"10.3390\/cells9081748"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States. <i>J. Urol.<\/i>, <b>186<\/b>, 540\u2013544 (2011).","DOI":"10.1016\/j.juro.2011.03.132"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kane KA, Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>2<\/b>, 193\u2013204 (1980).","DOI":"10.1097\/00005344-198003000-00010"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Patel BD, Palakundam N, Alamanda R, Gadekar AR, Raje AA, Ameta R. A simple and sensitive LC-MS\/MS method for quantification of Bepridil in rat plasma and its application to pharmacokinetic studies. <i>J. Pharm. Biomed. Anal.<\/i>, <b>172<\/b>, 113\u2013119 (2019).","DOI":"10.1016\/j.jpba.2019.04.038"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cox B, Lee TF. Is acetylcholine involved in a dopamine receptor mediated hypothermia in mice and rats? <i>Br. J. Pharmacol.<\/i>, <b>62<\/b>, 339\u2013347 (1978).","DOI":"10.1111\/j.1476-5381.1978.tb08466.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ninan I, Kulkarni SK. Dopamine receptor sensitive effect of dizocilpine on feeding behaviour. <i>Brain Res.<\/i>, <b>812<\/b>, 157\u2013163 (1998).","DOI":"10.1016\/S0006-8993(98)00990-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Wallace M, Duan R, Liu W, Locke C, Nothaft WA. Randomized, double-blind, placebo-controlled, crossover study of the T-type calcium channel blocker ABT-639 in an intradermal capsaicin experimental pain model in healthy adults. <i>Pain Med.<\/i>, <b>17<\/b>, 551\u2013560 (2016).","DOI":"10.1093\/pm\/pnv068"},{"key":"14","unstructured":"14) Lee M. Z944: a first in class T-type calcium channel modulator for the treatment of pain. <i>J. Peripher. Nerv. Syst.<\/i>, <b>19<\/b> (Suppl. 2), S11\u2013S12 (2014)."},{"key":"15","unstructured":"15) Nam G. T-type calcium channel blockers: a patent review (2012\u20132018). <i>Expert. Opin. Ther. Pat.<\/i>, <b>28<\/b>, 883\u2013901 (2018)."},{"key":"16","unstructured":"16) Tibbs GR, Posson DJ, Goldstein PA. Voltage-gated ion channels in the PNS: Novel therapies for neuropathic pain? <i>Trends Pharmacol. Sci.<\/i>, <b>37<\/b>, 522\u2013542 (2016)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sperelakis N. Electrophysiology of calcium antagonists. <i>J. Mol. Cell. Cardiol.<\/i>, <b>19<\/b> (Suppl. 2), 19\u201347 (1987).","DOI":"10.1016\/S0022-2828(87)80003-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tamura A, Ogura T, Uemura H, Reien Y, Kishimoto T, Nagai T, Komuro I, Miyazaki M, Nakaya H. Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current. <i>J. Pharmacol. Sci.<\/i>, <b>110<\/b>, 150\u2013159 (2009).","DOI":"10.1254\/jphs.08312FP"},{"key":"19","unstructured":"19) Asano T, Tanaka KI, Tada A, Shimamura H, Tanaka R, Maruoka H, Mizushima T, Takenaga M. Ameliorative effect of chlorpromazine hydrochloride on visceral hypersensitivity in rats: possible involvement of 5-HT<sub>2A<\/sub> receptor. <i>Br. J. Pharmacol.<\/i>, <b>174<\/b>, 3370\u20133381 (2017)."},{"key":"20","unstructured":"20) Ogata N, Narahashi T. Potent blocking action of chlorpromazine on two types of calcium channels in cultured neuroblastoma cells. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>252<\/b>, 1142\u20131149 (1990)."},{"key":"21","unstructured":"21) Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. <i>Life Sci.<\/i>, <b>68<\/b>, 29\u201339 (2000)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kuoppam\u00e4ki M, Palvimaki EP, Hietala J, Syvalahti E. Differential regulation of rat 5-HT<sub>2A<\/sub> and 5-HT<sub>2C<\/sub> receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. <i>Neuropsychopharmacology<\/i>, <b>13<\/b>, 139\u2013150 (1995).","DOI":"10.1016\/0893-133X(95)00049-J"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sekiguchi F, Fujita T, Deguchi T, <i>et al.<\/i> Blockade of T-type calcium channels by 6-prenylnaringenin, a hop component, alleviates neuropathic and visceral pain in mice. <i>Neuropharmacology<\/i>, <b>138<\/b>, 232\u2013244 (2018).","DOI":"10.1016\/j.neuropharm.2018.06.020"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/3\/44_b20-00742\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T03:36:59Z","timestamp":1615001819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/3\/44_b20-00742\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00742","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}